home / stock / adxs / adxs short
Short Information | Advaxis Inc. (OTCMKTS:ADXS)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 3,444 |
Total Actual Volume | 27,386 |
Short Trends | |
---|---|
Cover Days | 16 |
Short Days | 4 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 172 |
Average Short Percentage | 19.00% |
Is there a ADXS Short Squeeze or Breakout about to happen?
See the ADXS Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
01-03-2025 | $0.027 | $0.027 | $0.027 | $0.027 | 240 | 2 | 0.83% |
01-02-2025 | $0.027 | $0.027 | $0.027 | $0.027 | 255 | 6 | 2.35% |
12-05-2024 | $0.027 | $0.02705 | $0.02705 | $0.027 | 1,425 | 108 | 7.58% |
12-02-2024 | $0.1051 | $0.1051 | $0.1051 | $0.075 | 15,952 | 7 | 0.04% |
11-25-2024 | $0 | $0.027 | $0 | $0 | 195 | 7 | 3.59% |
11-20-2024 | $0.027 | $0.027 | $0.027 | $0.027 | 1,573 | 315 | 20.03% |
11-06-2024 | $0.02705 | $0.027 | $0.02705 | $0.027 | 1,290 | 81 | 6.28% |
11-05-2024 | $0.02705 | $0.02705 | $0.02705 | $0.02705 | 1,993 | 1,865 | 93.58% |
09-16-2024 | $0.02 | $0.02 | $0.02 | $0.02 | 117 | 4 | 3.42% |
09-13-2024 | $0.02 | $0.02 | $0.02 | $0.02 | 331 | 174 | 52.57% |
09-12-2024 | $0.02 | $0.02 | $0.02 | $0.02 | 956 | 300 | 31.38% |
09-10-2024 | $0.02 | $0.02 | $0.02 | $0.02 | 537 | 32 | 5.96% |
08-27-2024 | $0.02 | $0.02 | $0.02 | $0.02 | 504 | 12 | 2.38% |
08-26-2024 | $0.02 | $0.02 | $0.02 | $0.02 | 507 | 310 | 61.14% |
08-22-2024 | $0 | $0.0205 | $0 | $0 | 229 | 132 | 57.64% |
08-21-2024 | $0 | $0.0205 | $0 | $0 | 110 | 6 | 5.45% |
08-20-2024 | $0.0205 | $0.0205 | $0.0205 | $0.0205 | 175 | 24 | 13.71% |
08-15-2024 | $0.02025 | $0.02025 | $0.02025 | $0.02025 | 255 | 5 | 1.96% |
08-13-2024 | $0.02 | $0.02 | $0.02 | $0.02 | 611 | 52 | 8.51% |
08-12-2024 | $0 | $0.02 | $0 | $0 | 131 | 2 | 1.53% |
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...